Company / EPS (Diluted)
Rein Therapeutics, Inc. EPS (Diluted) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$3.51
FY2025
5-year range
-$6.02 / -$0.61
FY2021-FY2025
Trend
-2.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has fluctuated over the past 9 years, ranging from $-32.31 in FY2017 to $-0.61 in FY2021.
Based on SEC 10-K filings.
-3.51 in FY2025.
Improved from $-6.02 to $-3.51 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 2.6% year-over-year.
- Peak eps (diluted) was recorded in FY2021.
- Lowest eps (diluted) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.51 | -2.6% |
| FY2024 | -$3.42 | +43.2% |
| FY2023 | -$6.02 | -2.2% |
| FY2022 | -$5.89 | -865.6% |
| FY2021 | -$0.61 | +49.2% |
| FY2020 | -$1.20 | +43.9% |
| FY2019 | -$2.14 | +29.6% |
| FY2018 | -$3.04 | +90.6% |
| FY2017 | -$32.31 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026